The American Journal of Managed Care23 天
Postponed MacTel Treatment Approval Could Lead to Delay of Needed Care
MacTel type 2 is a rare retinal condition causing central vision loss, with no current treatments available. NT-501, a potential treatment for MacTel, has its FDA decision delayed to March 18 ...
Yahoo Finance1 个月
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type ...
The new PDUFA goal date for the biologics license application (BLA) of NT-501 (revakinagene taroretcel) as a treatment for Macular telangiectasia type 2 (MacTel) is March 18, 2025. "We are ...
Verywell Health on MSN6 个月
MacTel2 Treatment: With Easier Ways to Adapt to Vision Loss
Macular telangiectasia type 2 (MacTel2) causes gradual vision loss in both eyes. This condition is not curable, but ...